Compare Elastic NV (ESTC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Smith & Nephew plc — how do they compare? Elastic NV trades at $95.65 (market cap $10.00B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Elastic NV and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Smith & Nephew plc for 120 Days on average.
| ESTC | SNN | |
|---|---|---|
Market Cap | $10.00B | $11.10B |
Volume | 1,610,337 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $99.91 | $37.17 |
52-Week Low | $43.30 | $26.42 |
Typical Hold Time | 10 Days | 120 Days |
Enterprise Value | $9.14B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.10, down 1.59% today but maintains strong technical momentum with a bullish moving average signal. The company shows robust revenue growth with Q2 2026 EPS beating expectations at $0.70 versus $0.584, and analyst consensus remains strongly positive with 22 buy ratings and no sell recommendations. Recent product launches including AI-powered metrics and serverless vector database enhancements demonstrate ongoing innovation.
The outlook remains favorable with projected revenue growth to $1.8B in 2026 and net income turning positive to $376M. Key risks include high valuation multiples and competitive pressures in the enterprise software space. The consensus price target of $79.50 suggests potential downside from current levels despite strong fundamentals.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
